Cytokinetics (CYTK) Expected to Announce Quarterly Earnings on Tuesday

Cytokinetics (NASDAQ:CYTK) is projected to post its quarterly earnings results after the market closes on Tuesday, February 25th. Analysts expect Cytokinetics to post earnings of ($1.29) per share and revenue of $14.26 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Cytokinetics Trading Up 10.9 %

Shares of NASDAQ:CYTK opened at $46.16 on Tuesday. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics has a 52-week low of $40.53 and a 52-week high of $81.36. The stock has a market cap of $5.45 billion, a price-to-earnings ratio of -8.58 and a beta of 0.83. The business has a 50-day moving average price of $47.43 and a 200-day moving average price of $51.68.

Insider Activity at Cytokinetics

In other news, Director John T. Henderson sold 1,780 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.42, for a total value of $89,747.60. Following the transaction, the director now directly owns 38,461 shares of the company’s stock, valued at approximately $1,939,203.62. This trade represents a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Fady Ibraham Malik sold 7,300 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $50.16, for a total transaction of $366,168.00. Following the sale, the executive vice president now directly owns 111,878 shares of the company’s stock, valued at approximately $5,611,800.48. This represents a 6.13 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,122 shares of company stock valued at $1,402,056. 3.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $120.00 price objective on shares of Cytokinetics in a research note on Tuesday, January 21st. Royal Bank of Canada increased their price target on Cytokinetics from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 18th. Citigroup began coverage on Cytokinetics in a research note on Friday, February 7th. They set a “buy” rating and a $86.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a research note on Thursday, February 6th. Finally, JMP Securities reiterated a “market outperform” rating and set a $78.00 price target on shares of Cytokinetics in a research report on Friday, February 7th. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and an average price target of $82.00.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.